Catkin Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.60 M
- Revenue Growth 84.17%
- Profit Growth 493.57%
- Ebitda 288.98%
- Net Worth 68.45%
- Total Assets 15.23%
About Catkin Pharmaceuticals
Catkin Pharmaceuticals Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 03 June 2015 (Nine years and eight months 21 days old ). Its registered office is in Dehradun, Uttarakhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.60 M.
Sanjai Kumar, Ajay Gusain, and Sumit Kumar serve as directors at the Company.
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999UR2015PTC001533
- Company No.
001533
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jun 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Who are the key members and board of directors at Catkin Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjai Kumar  | Director | 03-Jun-2015 | Current |
| Ajay Gusain | Additional Director | 20-Apr-2018 | Current |
| Sumit Kumar | Director | 03-Jun-2015 | Current |
Financial Performance of Catkin Pharmaceuticals.
Catkin Pharmaceuticals Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 84.17% increase. The company also saw a substantial improvement in profitability, with a 493.57% increase in profit. The company's net worth Soared by an impressive increase of 68.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Catkin Pharmaceuticals?
In 2019, Catkin Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.60 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.06 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 Jun 2020 | Others | ₹0.10 M | Open |
| 10 Jan 2018 | Others | ₹0.50 M | Open |
How Many Employees Work at Catkin Pharmaceuticals?
Unlock and access historical data on people associated with Catkin Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Catkin Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Catkin Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
